JP2023552383A - ペプチド受容体放射性核種療法 - Google Patents

ペプチド受容体放射性核種療法 Download PDF

Info

Publication number
JP2023552383A
JP2023552383A JP2023533889A JP2023533889A JP2023552383A JP 2023552383 A JP2023552383 A JP 2023552383A JP 2023533889 A JP2023533889 A JP 2023533889A JP 2023533889 A JP2023533889 A JP 2023533889A JP 2023552383 A JP2023552383 A JP 2023552383A
Authority
JP
Japan
Prior art keywords
conjugate
peptide
cancer
mci
peg moiety
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023533889A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023552383A5 (https=
Inventor
ジュリー エル． サトクリフ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of JP2023552383A publication Critical patent/JP2023552383A/ja
Publication of JP2023552383A5 publication Critical patent/JP2023552383A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
    • A61K51/065—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules conjugates with carriers being macromolecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023533889A 2020-12-04 2021-12-03 ペプチド受容体放射性核種療法 Pending JP2023552383A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063121762P 2020-12-04 2020-12-04
US63/121,762 2020-12-04
PCT/US2021/061886 WO2022120226A1 (en) 2020-12-04 2021-12-03 Peptide receptor radionuclide therapy

Publications (2)

Publication Number Publication Date
JP2023552383A true JP2023552383A (ja) 2023-12-15
JP2023552383A5 JP2023552383A5 (https=) 2024-12-05

Family

ID=81853616

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023533889A Pending JP2023552383A (ja) 2020-12-04 2021-12-03 ペプチド受容体放射性核種療法

Country Status (9)

Country Link
US (1) US20240131206A1 (https=)
EP (1) EP4255891A4 (https=)
JP (1) JP2023552383A (https=)
KR (1) KR20230117581A (https=)
CN (1) CN116829541A (https=)
AU (1) AU2021390552A1 (https=)
CA (1) CA3203175A1 (https=)
MX (1) MX2023006483A (https=)
WO (1) WO2022120226A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025160502A1 (en) 2024-01-26 2025-07-31 The Regents Of The University Of California Peptide receptor radionuclide therapy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0282057A3 (en) * 1987-03-11 1990-03-07 The Board Of Regents Of The University Of Michigan Chemo-radio-immuno-conjugates
MX340566B (es) * 2007-03-27 2016-07-14 Radiomedix Inc Composiciones para formacion de imagen objetivo y terapia.
US20120015899A1 (en) * 2008-10-25 2012-01-19 Plant Bioscience, Limited Modified plant virus particles and uses therefor
WO2011082191A1 (en) * 2009-12-30 2011-07-07 Ge Healthcare Limited Method of using a 99mtc-labelled injection rgd compound and a [18f]-labelled rgd injection compound in external beam radiotherapy planning
CA2945945C (en) * 2014-04-15 2023-10-03 The Regents Of The University Of California Bi-terminal pegylated integrin-binding peptides and methods of use thereof
EP3468984A4 (en) * 2016-06-13 2020-03-11 The Regents of the University of California ALPHA (V) BETA (6) BINDING PEPTIDES AND METHODS OF USE THEREOF
MX2019005742A (es) * 2016-11-23 2019-09-13 Cancer Targeted Tech Llc Inhibidores de antigeno de membrana especifico de la prostata (psma) de union a albumina.
GB201706472D0 (en) * 2017-04-24 2017-06-07 Cancer Res Tech Ltd Tumour-targeting peptide variants
CN111032632B (zh) * 2017-05-30 2024-04-12 约翰霍普金斯大学 用于前列腺癌的腔内放射疗法的前列腺特异性膜抗原靶向的高亲和力剂
CN109091683B (zh) * 2018-08-10 2019-10-18 北京大学 一种用于整合素αvβ6靶向的环状多肽放射性药物及其制备方法
WO2021226432A2 (en) * 2020-05-08 2021-11-11 The Regents Of The University Of California Methods of detecting and treating lung damage in respiratory-related viral infections

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MOL IMAGING BIOL, vol. 16, JPN6025047602, 2014, pages 567 - 577, ISSN: 0005735484 *
MOL IMAGING BIOL, vol. 22, JPN6025047603, May 2020 (2020-05-01), pages 1543 - 1552, ISSN: 0005735483 *
MOLECULAR IMAGING, vol. 8, no. 2, JPN6025047601, 2009, pages 111 - 121, ISSN: 0005735485 *

Also Published As

Publication number Publication date
WO2022120226A1 (en) 2022-06-09
CN116829541A (zh) 2023-09-29
EP4255891A4 (en) 2026-03-18
AU2021390552A9 (en) 2024-06-20
AU2021390552A1 (en) 2023-06-29
CA3203175A1 (en) 2022-06-09
US20240131206A1 (en) 2024-04-25
EP4255891A1 (en) 2023-10-11
KR20230117581A (ko) 2023-08-08
MX2023006483A (es) 2023-07-20

Similar Documents

Publication Publication Date Title
Weiner et al. Radiolabeled peptides in oncology: role in diagnosis and treatment
US12605447B2 (en) Stable formulations for radionuclide complexes
KR102934560B1 (ko) 신장 보호 물질로서의 파라-아미노히푸르산(pah)
TWI605815B (zh) 用於製備包含阿米福丁與胺基酸之腎保護劑的組成物及方法
Zhang et al. Biodistribution and localization of iodine-131 labeled Metuximab in patients with hepatocellular carcinoma
KR20220006286A (ko) 전립선암 진단 및 치료를 위한 전립선특이 막 항원 표적 화합물 및 이를 포함하는 전립선암 진단 및 치료용 조성물
JP2023552383A (ja) ペプチド受容体放射性核種療法
US20240342322A1 (en) Netrin-1 detection, companion test and therapy based on radiations
JP2024500829A (ja) 治療診断剤として使用するための放射性標識α－Ｖβ－３及び／又はα－Ｖβ－５インテグリンアンタゴニスト
JP2025503096A (ja) がんの処置および撮像のための複合体
HK40103039A (zh) 肽受体放射性核素治疗
WO2025160502A1 (en) Peptide receptor radionuclide therapy
Ahmad The Use of Bioorthogonal Chemistry to Create 99mTc and Micelle-based Diagnostic Agents
WO2026083399A1 (en) Conjugates and use of same for theranostics
Class et al. Patent application title: COMPOSITIONS AND METHODS FOR THE PREPARATION OF KIDNEY PROTECTIVE AGENTS COMPRISING AMIFOSTINE AND AMINO ACIDS Inventors: Ebrahim Delpassand (Houston, TX, US) Izabela Tworowska (Houston, TX, US) Sanjay Thamake (Houston, TX, US) David Ranganathan (Houston, TX, US)
JP2015083546A (ja) 癌の原発巣・骨転移の検査・治療用放射性標識薬剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230803

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241127

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241127

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251120

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260318